The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2019Validation of Microglial CRAC Channels as a Therapeutic Target for Parkinson’s Disease
Study Rationale:
Inflammation of the central nervous system mediated by microglial cells is a major feature of Parkinson’s disease. Vivreon Biosciences is developing Parkinson’s disease therapeutics... -
Research Grant, 2019Determining the Level of LRRK2 Inhibition Required for Therapeutic Efficacy
Study Rationale:
While inhibitors of LRRK2 activity are currently in clinical trials for the treatment of Parkinson’s disease, the minimum requirement of target engagement to significantly modify... -
Therapeutic Pipeline Program, 2019Mapping Brain Response Patterns to Deep Brain Stimulation with FMRI
Study Rationale:
Deep brain stimulation (DBS) targets malfunctioning brain circuits. Commonly used to treat Parkinson’s disease (PD), this surgical therapy can produce striking clinical benefits when... -
Epidemiological Parkinson's Risk Modifiers, 2019Study in Norwegian Population to Identify Therapies with Repurposing Potential for Parkinson’s Disease
Study Rationale:
There are not yet medicines that can prevent or slow Parkinson’s disease. Developing a new therapeutic can cost up to 2.6 billion dollars and takes many years of screening, chemistry... -
Therapeutic Pipeline Program, 2019Managing Levodopa-induced Dyskinesias by Targeting Dopamine D1 Receptor Signaling
Study Rationale:
Parkinson’s is a complex brain disease caused by the gradual loss of brain cells producing the neurotransmitter dopamine, which controls movement, emotion and affect. However... -
Access to Data and Biospecimens, 2019Convergence of LRRK2 and GBA in the Pathogenesis of Parkinson’s Disease Supplement
Promising Outcomes of Original Grant:
In our original project we used dopamine cells derived from induced pluripotent stem cells (iPSCs) from people with Parkinson’s-associated LRRK2 or GBA mutations...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.